Abstract
ABSTRACT The effect of orally administered 17α-ethyl-17β-hydroxy-19-norandrost-4-en-3-one (75 mg daily during 8 days) on the urinary excretion of 17-ketosteroids, total 17-hydroxycorticosteroids and uropepsin and on the gastric secretory activity has been studied in 10 male patients with peptic ulcers. The excretion of 17-ketosteroids was significantly reduced, but the excretion of total 17-hydroxycorticosteroids and uropepsin and gastric secretory activity were not affected by the treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
